Formation of platinum-DNA adducts in pediatric patients receiving carboplatin

Pharmacotherapy

Volumn 16, Issue 4, 1996, Pages 631-637

  Tonda, Margaret E ^a   Murry, Daryl J ^a   Rodman, John H ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DNA; ETOPOSIDE; IFOSFAMIDE; PLATINUM;

ADOLESCENT; ADULT; ARTICLE; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DNA ADDUCT; DOSE RESPONSE; DRUG DNA BINDING; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; SOLID TUMOR;

ADULT; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; DNA ADDUCTS; FEMALE; HUMANS; INFANT; LEUKOCYTES; MALE; NEOPLASMS; PLATINUM; PROSPECTIVE STUDIES;

EID: 0029835814     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann Intern Med 1984;100:704-13.
2. Jaffe N, Knopp J, Chuang VP, et al. Osteosarcoma: intra-arterial treatment in the primary tumor with cis-diamminedichloroplatinum (II) (CDP): angiographic, pathologic and pharmacological studies. Cancer 1983;51: 402-7.
3. Pratt CB, Hayes A, Green AA, et al. Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors; a phase II study. Cancer Treat Rep 1981;65:1021-6.
4. Wagstaff AJ, Ward A, Benfield P, Heel RC. Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 1989;37:162-90.
5. Pinkerton CR, Broadbent V, Horwich A, et al. "JEB" - a carboplatin-based regimen for malignant germ cell tumors in children. Br J Cancer 1990;62:257-62.
6. Kahn AB, D'Souza B, Wharam M, et al. Cisplatin therapy in recurrent brain tumors. Cancer Treat Rep 1982;66:2013-20.
7. Gaynon PS, Ettinger LJ, Baum ES, Siegel SE, Krailo MD, Hammond GD. Carboplatin in childhood brain tumors: a children's cancer study group phase II trial. Cancer 1990;66:2465-9.
8. Allen JC, Walker R, Luks E, Jennings M, Barfoot S, Tan C. Carboplatin and recurrent childhood brain tumors. J Clin Oncol 1987;5:459-63.
9. Fichtinger-Schepman AMJ, van Oosterom AT, Lohman PHM, Berend Frits. Cis-diamminedichloroplatinum (II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum (II). Cancer Res 1987;47:3000-4.
10. Fichtinger-Schepman AMJ, van der Veer JL, den Hartog JHJ, Lohman PHM, Reedijk J. Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification, and quantitation. Biochemistry 1985;24:707-13.
11. Fichtinger-Schepman AMJ, van der Velde-Visser SD, van Dijk-Knijnenburg HCM, van Oosterom AT, Baan RA, Berends F. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation. Cancer Res 1990;50:7887-94.
12. Dijit FJ, Fichtinger-Schepman, Berends F, Reedijk J. Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res 1988;48:6058-62.
13. Blommaert FA, van Dijk-Knijnenburg HCM, Dijt FJ, et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 1995;34:8474-80.
14. Poirier MC, Lippard SJ, Zwelling LA, et al. Antibodies elicited against cis-diamminedichloroplatinum (II)-modified DNA are specific for cis-diamminedichloroplatinum (II)-DNA adducts formed in vivo and in vitro. Proc Natl Acad Sci USA 1982;79:6443-7.
15. Reed E, Sauerhoff S, Poirier MC. Quantitation of platinum-DNA binding after therapeutic levels of drug exposure - a novel use of graphite furnace spectrometry. Atomic Spectroscopy 1988;9:93-5.
16. Poirier MC, Reed E, Litterst CL, Katz D, Gupta-Burt S. Persistence of platinum-amine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients. Cancer Res 1992;52:149-53.
17. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987;84:5024-8.
18. Reed E, Yuspa ST, Zwelling LA, Ozols RF, Poirier MC. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 1986;77:545-50.
19. Reed E, Ozols RF, Tarone R, Yuspa SH, Poirier MC. The measurement of cisplatin-DNA adduct levels in testicular cancer patients. Carcinogenesis 1988;9:1909-11.
20. Reed E, Ostchega Y, Steinberg SM, et al. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. Cancer Res 1990;50:2256-60.
21. Reed E, Parker RJ, Gill I, et al. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 1993;53:3694-9.
22. Marina NM, Rodman JH, Shema SJ, et al. Phase 1 study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 1993;11:554-60.
23. Rodman JH, Maneval DC, Magill HI, Sunderland M. Measurement of Tc-99m DTPA serum clearance for estimating glomerular filtration rate in children with cancer. Pharmacotherapy 1993;13:10-16.
24. Murry DJ, Sandlund JT, Stricklin LM, Rodman JH. Pharmacokinetics and acute renal effects of continuously infused carboplatin. Clin Pharmacol Ther 1993;54:374-80.
25. Newell DR, Pearson ADL, Balmanno K, et al. Carboplatin pharmacokinetic in children: the development of a pediatric dosing formula. J Clin Oncol 1993;11:2314-23.
26. Riccardi R, Riccardi A, Losorella A, et al. Clinical pharmacokinetics of carboplatin in children. Cancer Chemother Pharmacol 1994;33:477-83.
27. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-8.
28. Ma J, Verwei J, Planting A, et al. Current sample handling methods for measurement of platinum-DNA adducts in leukocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br J Cancer 1995;71:512-17.
29. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992;89:3070-4.
30. Ishikawa T, Ali-Osman F. Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 1993;268:20116-25.
31. Motzer RJ, Reed E, Perera F, et al. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 1994;73:2843-52.